Chimeric antigen T cell receptor treatment in hematological malignancies.
作者信息
Ali Natasha
机构信息
Department of Pathology and Laboratory Medicine/Oncology, Aga Khan University, Karachi, Pakistan.
出版信息
Blood Res. 2019 Jun;54(2):81-83. doi: 10.5045/br.2019.54.2.81. Epub 2019 Jun 25.
Abstract
摘要
相似文献
1
Chimeric antigen T cell receptor treatment in hematological malignancies.嵌合抗原T细胞受体疗法治疗血液系统恶性肿瘤。
Blood Res. 2019 Jun;54(2):81-83. doi: 10.5045/br.2019.54.2.81. Epub 2019 Jun 25.
2
Adoptive immunotherapy for hematological malignancies: Current status and new insights in chimeric antigen receptor T cells.血液系统恶性肿瘤的过继性免疫治疗：嵌合抗原受体T细胞的现状与新见解
Blood Cells Mol Dis. 2016 Nov;62:49-63. doi: 10.1016/j.bcmd.2016.11.001. Epub 2016 Nov 10.
3
Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies.迅速传播：嵌合抗原受体T细胞疗法治疗血液系统恶性肿瘤
Immunol Rev. 2015 Jan;263(1):68-89. doi: 10.1111/imr.12243.
4
Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data.嵌合抗原受体T细胞疗法治疗B细胞血液系统恶性肿瘤：关键临床试验数据更新
Pharmaceutics. 2020 Feb 24;12(2):194. doi: 10.3390/pharmaceutics12020194.
5
[Chimeric antigen receptor T-cell therapy for hematological malignancies].[嵌合抗原受体T细胞疗法治疗血液系统恶性肿瘤]
Rinsho Ketsueki. 2019;60(9):1351-1357. doi: 10.11406/rinketsu.60.1351.
6
Enhancement of the in vivo persistence and antitumor efficacy of CD19 chimeric antigen receptor T cells through the delivery of modified TERT mRNA.通过递送修饰的端粒酶逆转录酶（TERT）mRNA增强CD19嵌合抗原受体T细胞在体内的持久性和抗肿瘤功效。
Cell Discov. 2015 Dec 8;1:15040. doi: 10.1038/celldisc.2015.40. eCollection 2015.
7
Adoptive therapy with CAR redirected T cells for hematological malignancies.嵌合抗原受体修饰 T 细胞过继免疫疗法治疗血液系统恶性肿瘤。
Sci China Life Sci. 2016 Apr;59(4):370-8. doi: 10.1007/s11427-016-5036-3. Epub 2016 Mar 22.
8
Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.嵌合抗原受体 T 细胞疗法治疗血液系统恶性肿瘤和实体瘤：临床数据现状、当前局限性和展望。
Curr Res Transl Med. 2017 Sep;65(3):93-102. doi: 10.1016/j.retram.2017.08.003.
9
[Chimeric antigen receptor T cells for hematological malignancies: current understanding and future challenge].[用于血液系统恶性肿瘤的嵌合抗原受体T细胞：当前认识与未来挑战]
Zhonghua Nei Ke Za Zhi. 2019 Nov 1;58(11):793-795. doi: 10.3760/cma.j.issn.0578-1426.2019.11.001.
10
Survival outcomes and efficacy of autologous CD19 chimeric antigen receptor-T cell therapy in the patient with diagnosed hematological malignancies: a systematic review and meta-analysis.自体CD19嵌合抗原受体T细胞疗法在确诊血液系统恶性肿瘤患者中的生存结局和疗效：一项系统评价和荟萃分析
Ther Clin Risk Manag. 2019 May 6;15:637-646. doi: 10.2147/TCRM.S203822. eCollection 2019.
引用本文的文献
1
Aging and immunotherapies: New horizons for the golden ages.衰老与免疫疗法：黄金时代的新视野。
Aging Cancer. 2020 Dec;1(1-4):30-44. doi: 10.1002/aac2.12014. Epub 2020 Sep 30.
2
A Primer on Chimera Associated Receptor T-Cells.嵌合抗原受体 T 细胞概述。
Mo Med. 2021 Sep-Oct;118(5):460-465.
3
Programmable and multi-targeted CARs: a new breakthrough in cancer CAR-T cell therapy.可编程和多靶向 CAR：癌症 CAR-T 细胞治疗的新突破。
Clin Transl Oncol. 2021 Jun;23(6):1003-1019. doi: 10.1007/s12094-020-02490-9. Epub 2020 Sep 30.
4
Advancing CAR T-Cell Therapy for Solid Tumors: Lessons Learned from Lymphoma Treatment.推进实体瘤的嵌合抗原受体T细胞疗法：从淋巴瘤治疗中汲取的经验教训。
Cancers (Basel). 2020 Jan 3;12(1):125. doi: 10.3390/cancers12010125.
5
Immune Therapy for Liver Cancers.肝癌的免疫治疗
Cancers (Basel). 2019 Dec 27;12(1):77. doi: 10.3390/cancers12010077.
本文引用的文献
1
Chimeric antigen receptor T‑cell therapy-a hematological success story.嵌合抗原受体T细胞疗法——血液学领域的成功典范。
Memo. 2018;11(2):116-121. doi: 10.1007/s12254-018-0409-x. Epub 2018 Jun 6.
2
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.替沙格赛定用于治疗儿童和年轻成人B细胞淋巴细胞白血病
N Engl J Med. 2018 Feb 1;378(5):439-448. doi: 10.1056/NEJMoa1709866.
3
Chimeric antigen receptor T-cell therapies for multiple myeloma.用于多发性骨髓瘤的嵌合抗原受体T细胞疗法。
Blood. 2017 Dec 14;130(24):2594-2602. doi: 10.1182/blood-2017-06-793869. Epub 2017 Sep 19.
4
Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.嵌合抗原受体 T 细胞疗法 - 毒性的评估和管理。
Nat Rev Clin Oncol. 2018 Jan;15(1):47-62. doi: 10.1038/nrclinonc.2017.148. Epub 2017 Sep 19.
5
Chimeric Antigen Receptor T Cell Therapy in Hematology.血液学中的嵌合抗原受体T细胞疗法。
Turk J Haematol. 2015 Dec;32(4):285-94. doi: 10.4274/tjh.2015.0049. Epub 2015 Aug 6.
6
Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials.在成年急性髓性白血病患者的诱导化疗中添加吉妥珠单抗奥唑米星：来自随机对照试验的个体患者数据的荟萃分析。
Lancet Oncol. 2014 Aug;15(9):986-96. doi: 10.1016/S1470-2045(14)70281-5. Epub 2014 Jul 6.
7
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.19-28z嵌合抗原受体T细胞疗法治疗B细胞急性淋巴细胞白血病的疗效及毒性管理
Sci Transl Med. 2014 Feb 19;6(224):224ra25. doi: 10.1126/scitranslmed.3008226.
8
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.嵌合抗原受体修饰 T 细胞抗 CD19 治疗的临床试验中，B 细胞耗竭和恶性肿瘤缓解，以及细胞因子相关毒性。
Blood. 2012 Mar 22;119(12):2709-20. doi: 10.1182/blood-2011-10-384388. Epub 2011 Dec 8.
9
Hematopoietic stem cell transplantation for MDS.骨髓增生异常综合征的造血干细胞移植。
Hematol Oncol Clin North Am. 2010 Apr;24(2):407-22. doi: 10.1016/j.hoc.2010.02.003.
10
Targeting tumours with genetically enhanced T lymphocytes.利用基因增强的T淋巴细胞靶向肿瘤。
Nat Rev Cancer. 2003 Jan;3(1):35-45. doi: 10.1038/nrc971.
Zotero 插件